ABEO earnings analysis
What we found in ABEO's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Abeona’s commercial ramp continued, with revenue of $11.380 million, approximately 26% above the prior quarter, and ZEVASKYN revenue up 31% sequentially. However, diluted EPS declined to $(0.35) from $(0.30), revenue missed the $12.342 million consensus estimate, and cash was $146.8 million against approximately negative $22 million of quarterly free cash flow. The principal adverse development is continuing manufacturing and release-test uncertainty, including a July 2026 batch that could not be released as commercial product; no quantitative forward guidance was provided.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- ZEVASKYN revenue continued to expand
- Revenue was $11.380 million, up approximately 26% from $9.0 million in the prior quarter and substantially above $0.4 million in the year-ago quarter. ZEVASKYN revenue increased 31% sequentially to $11.380 million.
- Commercial revenue ramp continued
- The company reported $11.380 million of quarterly revenue, but diluted EPS was $(0.35), compared with $(0.30) in 2026 Q1, indicating sequentially wider per-share losses.
- No material control deficiencies reported
- Disclosure controls were concluded effective as of June 30, 2026, and the company reported no changes in internal control over financial reporting that materially affected, or were reasonably likely to materially affect, controls during the quarter.
- No new legal or insider-trading issues
- The filing reports no legal proceedings and states that none of the company’s directors or officers adopted, modified, or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading arrangement during the three months ended June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Commercial manufacturing remains constrained
- A ZEVASKYN batch manufactured after a July 2026 patient biopsy could not be released as commercial product because a cellular identity test was out of specification. The FDA authorized release only under a single-patient IND, and the company cannot guarantee acceptance of its proposed specification revision.
- Release-test failures threaten supply
- The filing identifies at least 2 material manufacturing-release events: a batch following an August 2025 biopsy was rejected after a false-positive sterility result, and a batch following a July 2026 biopsy failed a cellular identity specification. Such issues could adversely affect cash flow and results.
- Cash burn remains substantial
- The company reported $146.8 million of cash while quarterly free cash flow was approximately negative $22 million, indicating continued liquidity consumption as commercialization scales.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.35
- Segment
- ZEVASKYN: $11.380 million of revenue, up 31% sequentially; no other reportable segment revenue disclosed
What they said about what is next.
No formal quantitative revenue or EPS guidance was provided in the filing; outlook was deferred to the earnings release or call.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 13, 2026
- Abeona Therapeutics reported Q1 2026 results with net product revenue of $8.72 million, a stark increase from zero revenue in Q1 2025 due to the FDA approval of ZEVASKYN®. While the net loss widened to $(17.1) million…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ABEO makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever